

## Insulin resistance: impact on therapeutic developments in diabetes

Clifford J Bailey

Correspondence to:

Clifford J. Bailey,

School of Life and Health Sciences,

Aston University,

Birmingham B4 7ET, UK

c.j.bailey@aston.ac.uk

Tel +44 121 204 3898

Fax +44 121 204 4187

Abstract

Introduction

Multifactorial pathophysiology

Glucose-lowering agents (by class)

Future

## **Abstract**

Insulin resistance has a broad pathogenic impact affecting metabolic, cardio-renal and other disease areas. Extensive studies to dissect the mechanisms of insulin resistance have provided valuable insights to shape current clinical awareness and advance therapeutic practice. However, the development of direct interventions against insulin resistance have been hindered by its complex and highly variable presentations, especially in type 2 diabetes. Amongst glucose-lowering agents, metformin and thiazolidinediones provide cellular actions that counter some effects of insulin resistance: reduced glucotoxicity and weight-lowering with antidiabetic therapies also improve insulin action, excepting that endogenously- or exogenously-created hyperinsulinaemia may partially compromise these benefits. Increasing awareness of the pervasive and damaging ramifications of insulin resistance heightens the need for more specifically targeted and more effective therapies.

## **Introduction**

This short review is written in recognition of the seminal works of Gerald Reaven on the role of insulin resistance in the pathogenesis of type 2 diabetes and cardiovascular (CV) disease. Foregoing reviews in this issue of *Diabetes and Vascular Disease Research* have eminently recounted these works [1-4]. Here we consider how a growing appreciation of insulin resistance influenced the development of new therapeutics in the field of diabetes.

## **Multifactorial pathophysiology**

Reaven's Syndrome X (not to be confused with the cardiac syndrome X) describes the clustering of CV risk factors that depend on, or associate with insulin resistance [5]. Although Reaven's Syndrome X later became subsumed within the so-called Metabolic Syndrome, the two syndromes are not synonymous: insulin resistance can promote CV disease independently of other CV risk factors commonly included in the Metabolic Syndrome such as excess adiposity, and insulin resistance is often associated with compensatory hyperinsulinaemia, at least in its early pathogenesis, which further aggravates metabolic, vascular and haemodynamic disturbances [6, 7]. Studies on the aetiology of insulin resistance and accompanying metabolic and CV abnormalities gave rise to a 'common soil' hypothesis of shared origins, and clinical practice recognised that the presence of one feature associated with insulin resistance should prompt suspicion about other CV risk factors [8]. This in turn has promoted a more holistic multifactorial approach to the assessment and management of type 2 diabetes to accommodate metabolic and cardio-renal aspects [9, 10].

Insulin resistance presents across a wide variety of phenotypes with different responses between tissues, organs and physiological systems. Because this is typically due to multiple 'bottle-necks' in the signalling pathways that mediate the biological actions of insulin it has not been possible to identify a single cure-all molecular target [2]. However, several glucose-lowering agents can ameliorate the effects of insulin resistance with impact on diabetic complications, particularly in type 2 diabetes (Figure 1).

## **Insulin**

When Harold Himsworth described insulin resistance in the 1930s he energized debate about different types of diabetes [11]. Studies by Yalow and Berson in the late 1950s noted that insulin

concentrations might actually be higher in the early stages of ‘maturity-onset diabetes’, which substantiated the Himsworth premise [12]. Indeed, excess insulin has been mooted as a possible atherogenic factor [13], and concern about the use of high doses of insulin therapy was highlighted by evidence that raised insulin concentrations do not rectify insulin resistance and may lead to an increasing spiral of insulin demand through further disruption to insulin receptor binding and post-receptor signalling [14]. Thus, an appreciation of Syndrome X helped to redirect attention towards sparing insulin rather than increasing insulin, particularly in the earlier stages of type 2 diabetes.

While this illustrates the rationale for changing the management focus of type 2 diabetes beyond insulin, the main alternative up to the 1990s was the use of sulfonylureas which act mostly by stimulating insulin secretion.

### **Sulfonylureas**

The first sulfonylureas (eg carbutamide and tolbutamide) from the mid 1950s, and more potent versions from the mid 1960s (eg glibenclamide) have well-studied glucose-lowering properties in type 2 diabetes, but incur weight gain and risk of hypoglycaemia [15]. However, the effects of sulfonylureas on insulin resistance have not been consistent, and CV effects are also unclear. The much criticised University Group Diabetes Program (UGDP) cast doubt on the CV safety of tolbutamide in the late 1960s [16], but the United Kingdom Prospective Diabetes Study (UKPDS) and many other trials have shown a better CV prognosis with sulfonylureas than diet/lifestyle but less beneficial than metformin [17, 18]. Similarly, the effects of meglitinides on insulin resistance and CV events remain unclear but appear minimal. Nevertheless, the detrimental impact of hypoglycaemia on CV events and the adverse effects of insulin resistance on islet beta-cell function must be considered in selecting glucose-lowering therapies [19, 20].

### **Biguanides**

Although several guanidine derivatives were used in the treatment of diabetes in the 1920s and 1930s, their use dwindled as insulin became available, and it was not until the late 1950s that three biguanides (metformin, phenformin, and buformin) were introduced in Europe and one (phenformin) was introduced into the USA [21]. Phenformin and buformin were withdrawn in the late 1970s due to high risk of lactic acidosis, and metformin was eventually introduced into the USA in 1995. Since biguanides lower blood glucose in type 2 diabetes without stimulating insulin secretion it was acknowledged that they counter insulin resistance, and this was initially attributed to increased anaerobic metabolism and an independent reduction of hepatic gluconeogenesis. Lack of weight gain and low risk of hypoglycaemia favoured early use of metformin in type 2 diabetes, supported by mounting evidence for long-term reductions in CV disease [18, 22]. Through increased appreciation of the pathogenic effects of insulin resistance, Reaven’s studies contributed an important part of the scientific platform for metformin and its present-day position as first-line pharmacological therapy for type 2 diabetes. Reaven’s group also conducted several key studies on the mode of action of metformin, for example showing the inter-relationship of effects on glucose and lipid homeostasis [23]. The group also noted that metformin prolongs insulin receptor tyrosine kinase activity [24].

### **Thiazolidinediones**

Thiazolidinediones (TZDs) emerged from lipid-lowering clofibrate analogues in the mid 1970s, before peroxisome proliferator-activated receptor (PPAR) molecules had been discovered, but it was not until the late 1990s that the first PPAR $\gamma$  agonist (troglitazone) was introduced and then withdrawn due to unexplained hepatotoxicity. Rosiglitazone and pioglitazone followed promptly: they lowered plasma glucose without raising insulin, mostly through genomic effects that include differentiation of new small insulin-sensitive subcutaneous adipocytes, and improved insulin action in liver and muscle [25]. Pioglitazone also has some PPAR $\alpha$  agonism which assists lipid control, but weight gain associated with adipose deposition, renal effects to increase fluid retention and risk of heart failure limited their use. Rosiglitazone was withdrawn in Europe in 2010 amid controversy over possible adverse CV effects, and potential risk of bone fractures has further limited use. Although TZDs provided an antidote to insulin resistance, their limitations illustrate the complexities and ambiguities of increasing insulin action across a breadth of biological functions without modulating effects in different tissues [26].

### Incretins

Emanating from studies of the entero-insular axis, the availability of glucagon-like peptide-1 receptor agonists (GLP-1RAs) from 2005 and dipeptidyl peptidase-4 (DPP4) inhibitors from 2006 shifted the therapeutic focus of type 2 diabetes back to the pancreas. These agents do not carry the risk of hypoglycaemia seen with sulfonylureas because they potentiate insulin secretion and suppress glucagon secretion in a glucose-dependent manner (sulfonylureas stimulate insulin secretion independently of the glucose concentration) [27, 28]. Interestingly, GLP-1 RAs and DPP4 inhibitors reduce insulin resistance: this appears to be due, at least in part, to a lowering of glucose concentrations, interrupting the vicious spiral of type 2 diabetes in which insulin resistance generates hyperglycaemia and the ensuing glucotoxicity aggravates insulin resistance [20]. The satiety effect of GLP-1RAs, which is associated with weight loss and decreased adiposity, provides further metabolic and endocrine mechanisms to reduce insulin resistance, and potential additional incretin-based therapies including peptide YY (PYY), oxytomodulin, derivatives of gastric inhibitory polypeptide (GIP) and antagonists of ghrelin are under investigation [29].

### Sodium/glucose co-transporter-2 (SGLT2) inhibitors

SGLT2 inhibitors introduced in 2012 reduce glucotoxicity and adiposity by eliminating excess glucose in the urine, and thereby act indirectly to reduce insulin resistance and spare some of the demand on beta-cell function [30, 31]. Further evidence that lowering blood glucose will in turn lower insulin resistance is provided by alpha-glucosidase inhibitors which reduce prandial glucose excursions by slowing the rate of carbohydrate digestion.

### Adipose and anti-obesity agents to reduce weight

Excess lipids, endocrine factors and pro-inflammatory molecules from adipose tissue are well known to promote the pathogenesis of insulin resistance in obese type 2 diabetes, and several adipokine-based therapies such as adiponectin receptor agonists are receiving consideration as potential approaches to counter insulin resistance. Improvements of insulin action and glycaemic control are consistently reported with caloric restriction and reduced adipose mass (particularly in omental, hepatic and pancreatic locations), whether achieved by dieting, bariatric procedures, SGLT2

inhibitors, GLP-1RAs or other appetite/satiety-modifying therapies [32, 33]. We may wonder why the age-old energy-reducing approach to treating obese-diabetes has taken so long to regain prominence.

### **Cardiovascular and other considerations**

It is perhaps an irony that one of the TZDs (rosiglitazone), which improved insulin sensitivity and reduced a range of atherogenic risk markers, should have triggered CV safety concerns and prompted current regulatory requirements for specific and extensive evaluation of CV events with new glucose-lowering agents [26]. Although there are many unanswered questions regarding the subtle interplay of insulin resistance and hyperinsulinaemia on the endothelium and myocardium, it is evident that early intervention to achieve long-term metabolic control and reduce insulin resistance provides an opportunity to improve CV prognosis [18, 26]. Timing appears to be especially important in this context because late interventions have been less successful against CV disease. The early development of hyperinsulinaemia with insulin resistance may promote hyperfiltration and damage to glomeruli, and insulin resistance is implicated in a wide variety of conditions including polycystic ovary syndrome and dementia indicating the breadth of potential benefits to be gained from effective timely interventions [1-4, 34, 35].

### **Future**

Awareness of insulin resistance as an underlying and modifiable pathogenic factor spanning diabetes, CV and other disease areas makes it an important therapeutic target. However, despite considerable appreciation of insulin-receptor interactions and post-receptor signalling, therapeutic interventions have been unable to rectify or circumvent the complex multi-dimensional defects of insulin resistance [35]. Several current therapies do act, at least in part, to address the metabolic disturbances and provide some protection against adverse CV events associated with type 2 diabetes, but it is unclear how these interventions will impact other disease areas susceptible to insulin resistance. New therapeutic approaches, including small non-peptide molecules that partially mimic insulin effects at the insulin receptor, or initiate or potentiate receptor tyrosine kinase activity or target post-receptor pathways have been identified, but these are still at early stages of investigation [36 ]. Thus the therapeutic reversal of insulin resistance seems destined to be an ongoing unmet need for the foreseeable future.

### **References**

1. Reaven P. Insulin resistance: is the glass half empty or half full? *Diabetes Vasc Dis Res* 2019,
2. DeFronzo RA. Insulin resistance: organ, cellular, and molecular etiology. *Diabetes Vasc Dis Res* 2019,
3. King G. Insulin Resistance: Molecular and cardiovascular Implications. *Diabetes Vasc Dis Res* 2019,
4. Prentki M. Insulin Resistance as a physiologic defence against metabolic stress. *Diabetes Vasc Dis Res* 2019,

5. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes* 1988; 37:1595-607.
6. Reaven GM. Pathophysiology of insulin resistance in human disease. *Physiol Rev* 1995; 75: 473-86.
7. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. *Endocrinol Metab Clin North Am* 2004; 33: 283-303.
8. Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis. *Diabetes* 1995; 44:369-74.
9. Gaede P, Oellgaard J, Carstensen B, Rossing P et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. *Diabetologia* 2016, 59, 2298-2307.
10. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* 2018, 61: 2461-2498.
11. Reaven GM. Why Syndrome X? From Harold Himsworth to the Insulin Resistance Syndrome. *Cell Metab* 2005, 1, 1-9.
12. Yallow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. *J Clin Invest* 1960; 39: 1157-1175.
13. Stout RW. Insulin and atheroma. 20-yr perspective. *Diabetes Care* 1990; 13: 631-54
14. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. *Diabetes Care* 1991; 14: 173-194.
15. Khunti K, Chatterjee S, Gerstein HC, Zoungas S, Davies MJ. Do sulphonylureas still have a place in clinical practice? *Lancet Diabetes Endocrinol* 2018, 6, 821-832.
16. Schwartz TB, Meinert CL. The UGDP controversy: thirty-four years of contentious ambiguity laid to rest. *Perspect Biol Med* 2004; 47: 564-74.
17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998; 352: 837-853.
18. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 1998; 352: 854-865.
19. Hanefeld M, Frier BM, Pistrosch F. Hypoglycemia and cardiovascular risk: is there a major link? *Diabetes Care* 2016; 39: S205-S209
20. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. *Diabetologia* 2003, 46, 3-19.
21. Bailey CJ. Metformin: historical overview. *Diabetologia* 2017; 60:1566-1576.

22. Bailey CJ. Metformin: effects on micro and macrovascular complications in type 2 diabetes. *Cardiovasc Drugs Ther* 2008; 22: 215-24.
23. Jeppesen J, Zhou MY, Chen YDI, Reaven GM. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. *Diabetes Care* 1994; 17: 1093-1099.
24. Santos RF, Nomizo R, Wajhenberg BL, Reaven GM, Azhar S. Changes in insulin receptor tyrosine kinase activity associated with metformin treatment of type 2 diabetes. *Diabete Metab* 1995; 21: 274-80.
25. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. *Diabetes* 2005; 54: 2460-70.
26. Bailey CJ. Safety of antidiabetes medications: an update. *Clin Pharmacol Therap* 2015, 98, 185–195.
27. Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. *Diabetes Obes Metab* 2016; 18: 333-47.
28. Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. *Circulation* 2017; 136: 849-870.
29. Meier JJ, Nauck MA. Incretin-based therapies: where will we be 50 years from now? *Diabetologia* 2015, 58, 1745–1750.
30. Polidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. *Diabetologia* 2014; 57: 891–901.
31. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino T et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. *J Clin Invest* 2014; 124: 509–514.
32. Kusminski CM, Bickel PE, Scherer PE. Targeting adipose tissue in the treatment of obesity-associated diabetes. *Nature Reviews Drug Discovery* 2016, 15, 639–660
33. Kahan S, Fujioka K. Obesity pharmacotherapy in patients with type 2 diabetes. *Diabetes Spectrum* 2017; 30: 250-257.
34. Whaley-Connell A, Sowers JR. Insulin resistance in kidney disease: is there a distinct role separate from that of diabetes or obesity. *Cardiorenal Med* 2018, 8, 41-49.
35. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. *Physiol Rev* 2018, 98: 2133–2223.
36. Bailey CJ, Tahrani A, Barnett AH. Future glucose-lowering drugs for type 2 diabetes. *Lancet Diabetes Endocrinol* 2016, 4, 350-7.

#### **Legend to figure**

Figure 1. Timeline of some key events regarding insulin resistance and the introduction of diabetes therapies. Metformin was introduced in the USA in 1995. CSII, continuous subcutaneous insulin

infusion; CV, cardiovascular; DPP-4is, dipeptidyl peptidase-4 inhibitors; GLP-1RAs, glucagon-like peptide-1 receptor agonists; PCOS, polycystic ovary syndrome; SGLT-2is, sodium/glucose cotransporter-2 inhibitors; TZDs, thiazolidinediones.